Aditya Narayan

All Publications

• Societal costs associated with mothers of children with major congenital anomalies: a population-based matched cohort study in Denmark. BMJ public health Kim, K. M., Horváth-Puhó, E., Narayan, A., Wong, V., Skipper, N., Shah, N. R., Cohen, E., Toft Sørensen, H., Milstein, A. 2026; 4 (2): e003969

  Abstract

  To evaluate the 10-year economic burden experienced by mothers of children with major congenital anomalies in Denmark.Population-based matched retrospective cohort study.Denmark, 1 January 2007 to 31 December 2017.All women who gave birth to a singleton child with a major congenital anomaly during the study period (n=12 513). A comparison cohort of mothers with singleton births of children without major congenital anomalies was included, matched 1:10 by maternal age, parity and delivery year (n=125 008).Societal costs associated with mothers of children with major congenital anomalies. Costs were quantified as direct healthcare costs (primary care, outpatient, inpatient, psychiatric services and prescriptions) and indirect costs (productivity losses estimated using the human capital approach, including income, labour market contributions, supplementary pensions and fringe benefits).Direct costs peaked in the delivery year with a mean attributable cost of more than €1731 (95% CI €1634 to €1824). Indirect costs increased over time, reaching a peak of €2251 (95% CI €978 to €3442) at 9 years after delivery. Over a median follow-up of 6.3 years, attributable indirect costs were two and a half times higher than direct costs. Total societal costs associated with the 12 513 mothers of children with major congenital anomalies in our cohort were estimated at €152 million (95% CI €92 million to €219 million).Mothers of children with major congenital anomalies experienced substantial and persistent economic burdens, with indirect costs increasing over time and exceeding direct healthcare costs. These findings highlight the need for targeted public health and policy initiatives to support affected families and address long-term societal costs.

  View details for DOI 10.1136/bmjph-2025-003969

  View details for PubMedID 42299258

  View details for PubMedCentralID PMC13264895

• Early Life Adversity and Exposure to Secondhand Smoke among Children: Modeling Risk Health Behaviors and Increasing Environmental Tobacco Exposure JOURNAL OF CHILD & ADOLESCENT TRAUMA Alcala, H. E., Ng, A. E., Tkach, N., Narayan, A. 2026

  View details for DOI 10.1007/s40653-026-00902-6

  View details for Web of Science ID 001767418600001

• Reducing Intent to Leave and Creating Incentives for Physicians to Stay. JAMA network open Grover, A., Narayan, A. 2026; 9 (5): e2611048

  View details for DOI 10.1001/jamanetworkopen.2026.11048

  View details for PubMedID 42090159

• AI-augmented communication improves HIV PrEP initiation and persistence in populations disproportionately impacted by HIV. NPJ digital medicine Narayan, A., Blasingame, M., Warmuth, S., Palmeri, G., Halm, I., Bastani, R., Engeran-Cordova, W., Phillips, H. J., Mena, L., Shah, N. R. 2026

  Abstract

  This retrospective cohort study evaluated an AI-powered chatbot used for PrEP support across AIDS Healthcare Foundation clinics in the United States. Among 155,217 eligible adults, individuals who engaged with the chatbot had higher rates of PrEP initiation, follow-up attendance, and appointment adherence than non-users. Engagement was greatest among younger and racial or ethnic minority patients. Findings suggest that AI-supported communication may enhance aspects of PrEP care delivery.

  View details for DOI 10.1038/s41746-026-02519-3

  View details for PubMedID 41792418

• The promise and uncertainty of Medicare's ACCESS model. Health affairs scholar Narayan, A., Kocher, B. 2026; 4 (2): qxag018

  Abstract

  CMS's new ACCESS payment model is a novel approach in how Medicare pays for chronic-disease management: recurring, condition-specific payments tied to clinical improvement, rather than billing for discrete encounters or tightly defined remote-monitoring activities. The promise is straightforward, more reimbursement for technology-enabled longitudinal care and more choice and competition for patient care. But ACCESS leaves many questions unanswered about payment levels, how quality is measured, risk adjusted, and how these patients' facing technology-enabled services coordinate care with the traditional delivery systems. Whether ACCESS strengthens primary care will depend on the details.

  View details for DOI 10.1093/haschl/qxag018

  View details for PubMedID 41694245

  View details for PubMedCentralID PMC12898923

• Newborn Visits as Touchpoints to Bridge Postpartum Care Gaps. JAMA health forum Dewan, A. S., Narayan, A., Adashi, E. Y. 2025; 6 (9): e253608

  Abstract

  This Viewpoint discusses the benefits of and strategies for integrating postpartum screenings into newborn visits.

  View details for DOI 10.1001/jamahealthforum.2025.3608

  View details for PubMedID 41004179

• Shaping the Future of Senior Living: Technology-Driven and Person-Centric Approaches JOURNAL OF AGEING AND LONGEVITY Narayan, A., Shah, N. R. 2025; 5 (3)

  View details for DOI 10.3390/jal5030028

  View details for Web of Science ID 001798790500001

• Screening for Financial Toxicity and Health-Related Social Risks in Patients With GI Cancer: Results From a Large Cancer Center. JCO oncology practice Narayan, A., Lapen, K., Dee, E. C., Thom, B., Aviki, E. M., Chino, F. 2025: OP2500218

  Abstract

  Patients with GI cancers often face significant financial toxicity (FT) and health-related social risks (HRSRs), yet best practices for screening remain unclear. This study aimed to evaluate the prevalence of FT and HRSR and identify associated factors.From June 2022 to August 2023, patients were screened using the Comprehensive Score for Financial Toxicity (COST), patient-reported HRSR (eg, housing, food insecurity), and quality of life (QOL). Multivariate regressions were used to assess predictors of FT and HRSR, adjusting for several variables.Among 8,335 patients with GI cancer, 45% had a COST score of <26, indicating FT. In adjusted linear regression, FT was associated with racial/ethnic minority status (β, 4.20; P < .001), advanced disease (stage III [β, 1.33; P < .001]; IV [β, 1.56; P < .001]), recent treatment (β, 3.23; P < .001), and anal (β, 1.97; P = .003), esophageal (β, 1.66; P = .005), or hepatobiliary cancer (β, 1.05; P = .031). Older age (≥65 years [β, -5.17; P < .001]), higher income ($100,000-$200,000 [β, -1.81; P < .001]; >$200,000 [β, -3.80; P < .001]), and private insurance (β, -1.70; P < .001) were protective. Twenty-eight percent reported at least one HRSR. HRSRs were associated with minority status (odds ratio [OR], 2.14; P < .001), advanced disease (stage III [OR, 1.31; P = .001]; IV [OR, 1.24; P = .010]), recent treatment (OR, 1.20; P = .001), and gastric cancer (OR, 1.25; P = .027). Lower HRSR was associated with older age (OR, 0.59; P < .001), higher income ($100,000-$200,000 [OR, 0.66; P < .001]; >$200,000 [OR, 0.48; P < .001]), and private insurance (OR, 0.64; P < .001). Sex was not a predictor. Worst FT was associated with decreased QOL (β, -0.98; P < .001) and reduced medication adherence (β, 0.11; P < .001).High levels of FT and HRSR were observed in patients with GI cancer. Early intervention to address financial and social burdens may improve both disease and survivorship outcomes.

  View details for DOI 10.1200/OP-25-00218

  View details for PubMedID 40644642

• The Price and Quality of Methylphenidate Products. Journal of the American Academy of Child and Adolescent Psychiatry Narayan, A., Teasdale, B., Hudspeth, A. J., Light, D. Y., Nailor, J. K., Schulman, K. 2025

  Abstract

  OBJECTIVE: For many products, generic markets are very mature, with aggressive competition driving down the price of products for manufacturers. Under these conditions, manufacturers may not have an ability to invest in high-quality manufacturing processes.METHOD: We acquired samples of all available methylphenidate products in immediate release tablet (IR), extended-release tablet (ERT), and extended-release capsule (ERC) formulations in all available doses from all available labelers listed at one major wholesaler in February 2023. Products were analyzed for variations in dissolution parameters and for the presence of the N-nitroso-methylphenidate. Finally, we examined the cost and quality of tested products.RESULTS: All immediate-release methylphenidate products had similar dissolution profiles. For extended-release products, the confidence intervals of the difference factors for 12 of the 24 generic extended-release tablets sampled did not contain the null value, indicating a statistically significant difference in dissolution from the branded product. N-nitroso-methylphenidate, a probable human carcinogen, was detected above regulatory thresholds in generic immediate-release products for 7 of the 15 unique products sampled. N-nitroso-methlyphenidate was detected below regulatory thresholds in extended-release tablets and was not detected above the limit of quantification in extended-release capsules. The average price for products with and without elevated N-nitroso-methlyphenidate was not significantly different.CONCLUSION: Independent laboratory testing of generic methylphenidate products found significant product quality concerns. Making product quality transparent could offer the potential to dramatically improve the quality of generic drugs at no additional cost.

  View details for DOI 10.1016/j.jaac.2025.05.002

  View details for PubMedID 40381837

• The Future of Remote Patient Monitoring. Journal of general internal medicine Narayan, A., Adashi, E. Y. 2025

  View details for DOI 10.1007/s11606-025-09552-0

  View details for PubMedID 40329032

  View details for PubMedCentralID 10132045

• National Cancer System Characteristics and Prostate Cancer Outcomes: An Analysis of Global Data. The Prostate Dee, E. C., Iyengar, R., Narayan, A., Feliciano, E. J., Wu, J. F., Ho, F. D., Ng, K., Willmann, J., Cabaero, M. L., Tan, A. K., Lapen, K., Gorovets, D., Rathkopf, D. E., McBride, S. M., Nagar, H., Mahal, B. A., Nguyen, P. L. 2025

  Abstract

  Prostate cancer is the second most common cancer among men globally and the number of cases is expected to double from 2020 to 2040. A greater understanding of health system factors that can be leveraged to improve prostate cancer control may guide health system planning in anticipation of the growing global burden of prostate cancer.This ecological cross-sectional study made use of the most recent available national health system metrics for countries with prostate cancer incidence and mortality estimates available from the International Agency for Research on Cancer (IARC). IARC data represent the most updated estimates as of April 2025.National estimates of age-standardized mortality-to-incidence ratios (MIR) were derived from the GLOBOCAN 2022 database for male patients with prostate cancer of all ages. Health spending as a percent of gross domestic product, physicians per 1000 population, nurses and midwives per 1000 population, surgical workforce per 1000 population, gross domestic product (GDP) per capita, Universal Health Coverage Service Coverage Index (UHC index), availability of pathology services, human development index (HDI), gender inequality index, and number of radiotherapy centers per 1000 population were collected. The association between prostate MIR and each metric was evaluated using simple univariable linear regression models. Those with p < 0.005 (Bonferroni corrected) were included in multivariable models. Variation inflation factor analysis facilitated exclusion of variables with significant multicollinearity. R2 defined goodness of fit.Based on IARC estimate availability, data for 185 countries were collected; data availability ranged from 144 (77.8%, surgical workforce per 1000 population known) to 185 (100%, GDP per capita, RT centers per 1000 population). On univariable analysis, each of the 10 metrics was significantly associated with MIR of prostate cancer (< 0.001 forall). All but one (HDI, due to mutlicollinearity) were included in the multivariable model. The final multivariable model included 123 countries with complete data. Of those included in the regression with complete data, 44 of 123 (35.8%) were high-income countries; of those excluded due to incomplete data, 16 of 62 (25.8%) were high-income countries (χ² p = 0.17 comparing the proportion of high-income countries in the included and excluded groups). Therefore, the following variables were independently associated with lower (improved) MIR for prostate cancer: (1) surgical workforce per 1000 population, (2) UHC index, (3) radiotherapy centers per 1000 population, (4) GDP per capita. The final model had R2 of 0.8408.Analysis of global data and health-system metrics suggest that surgical workforce, degree of UHC, availability of radiotherapy centers, and GDP per capita are independently associated with improved prostate cancer outcomes. In leveraging individual countries' health systems as data points, these findings may guide health system planning and prioritization. Efforts to strengthen access to surgery and radiotherapy in the context of broader and equitable cancer system strengthening may represent concrete points of action for public health efforts, given the growing global burden of prostate cancer.

  View details for DOI 10.1002/pros.24901

  View details for PubMedID 40235173

• Medical Education. JAMA Narayan, A. 2025

  View details for DOI 10.1001/jama.2025.0797

  View details for PubMedID 40208573

• Piloting a community-based intervention to reduce medication theft among people experiencing homelessness Lee, H., Keen, R., Narayan, A. WILEY. 2025

  View details for DOI 10.1111/1475-6773.14542

  View details for Web of Science ID 001460552100032

• Evidence available and used by the Food and Drug Administration for the approval of orphan and nonorphan drugs. Health affairs scholar Koong, A. J., Irvin, V. L., Narayan, A., Song, S., Kaplan, R. M. 2025; 3 (4): qxaf057

  Abstract

  There are substantial financial incentives to develop orphan drugs for rare diseases, but concerns about the quality and volume of supporting evidence have emerged. We compare evidence used to evaluate orphan and nonorphan drugs approved by the Food and Drug Administration (FDA) between 2016 and 2023. This retrospective cross-sectional analysis utilizes FDA data on approvals and study information from ClinicalTrials.gov to compare characteristics of studies relevant to orphan and nonorphan drugs approved between 2016 and 2023. Of the 368 total drugs approved, 50% were orphan drugs. The FDA-approved drugs based on significantly fewer studies for orphan (1.5 studies/drug) compared to nonorphan (2.4 studies/drug). Additionally, a significantly lower proportion of studies were completed before FDA approval for orphan drugs (25% vs 41%). Orphan drugs were significantly less likely to be evaluated in randomized clinical trials (RCTs) (34% vs 63%). Of these RCTs, there were significantly fewer completed before approval (40% vs 54%) and that had results posted (35% vs 53%). There was a significant difference in the available evidence for orphan and nonorphan drugs. As new legislation like Cures 2.0 is developed, it is critical to examine the balance between an expedited approval timeline and the standard of clinical evidence.

  View details for DOI 10.1093/haschl/qxaf057

  View details for PubMedID 40190699

  View details for PubMedCentralID PMC11970248

• National cancer system characteristics and prostate cancer outcomes: A global analysis. Dee, E., Iyengar, R., Narayan, A., Feliciano, E., Nagar, H., Mahal, B. A., Nguyen, P. L. LIPPINCOTT WILLIAMS & WILKINS. 2025

  View details for DOI 10.1200/JCO.2025.43.5_suppl.24

  View details for Web of Science ID 001454740300026

• Cognitive, functional, and social disparities in patients receiving dialysis: a multi-site survey. Frontiers in health services Liou-Johnson, V., Narayan, A., Johnson, B. E., Shah, N. R., Odama, U. 2025; 5: 1688966

  Abstract

  End-stage kidney disease (ESKD) affects many Americans, with higher risks in certain subgroups of the US population. Differential kidney health outcomes may stem from non-medical social drivers of health, cognitive difficulties, and functional limitations. Recommendations for individuals with ESKD are often standardized and may not account for unique challenges and access barriers that individuals face. These challenges lead to preventable differences in access to treatments such as home dialysis and kidney transplantation. This study examines the prevalence of unmet social, cognitive, and functional needs amongst patients receiving dialysis and evaluates the intersection of these barriers to inform strategies to improve kidney health outcomes for all patients.In a cross-sectional study, a convenience sample of 962 patients from diverse backgrounds, currently undergoing dialysis from multiple dialysis centers across the United States (aged 21-95 years), were surveyed. Descriptive, Spearman's correlation, logistic regression, and Chi-Square Test analyses conducted.From our large sample, 45.1% reported memory challenges, 19.6% required assistance with activities of daily living (ADLs), and 51.0% experienced two or more mobility limitations. Additionally, 20.4% reported difficulty accessing healthcare, while 16.3% faced challenges obtaining medications. A subset (12.2%) of participants experienced overlapping social, cognitive, and functional barriers. Unmet needs were disproportionately higher amongst public insurance participants compared to those with private insurance, with 33.0% of Dual-eligible participants reporting three or more unmet needs.This study highlights the significant intersection of social, cognitive, and functional barriers faced by patients receiving dialysis with ESKD, particularly those from vulnerable populations. Addressing these multifaceted needs through person-centered interdisciplinary care models and policy interventions is critical to reducing disparities and improving outcomes in kidney health outcomes.

  View details for DOI 10.3389/frhs.2025.1688966

  View details for PubMedID 41641169

  View details for PubMedCentralID PMC12864511

• Parenthood and Paychecks-The Gender Pay Gap in Medicine. JAMA Kim, K. M., Narayan, A., Shah, N. R., Milstein, A. 2024

  View details for DOI 10.1001/jama.2024.22123

  View details for PubMedID 39470655

• TeleHelp Ukraine: A distributed international telemedicine response to the ongoing war. Journal of global health Narayan, A., Petryk, M., Savchuk, S., Villarino, K., Lopez, I., Morgun, E., Bakirova, A., Kamets, B., Le Tran, Q., Komzyuk, S., Kharbas, V., Asch, S., Pickering, A. 2024; 14: 04158

  Abstract

  Humanitarian crises frequently garner solidarity and robust volunteer recruitment among health care communities. However, a common obstacle is matching providers to those in need across geographic and other barriers. We examined the application of a decentralised governance strategy in establishing an emergency telemedicine response, TeleHelp Ukraine (THU).Using a case study approach, we explored how global networking and technological advancements empower organisations to generate, access, disseminate, and utilise knowledge for sustainable health care delivery.Preliminary results suggest that a non-profit, decentralised model strengthened by robust team dynamics may optimise the distribution of clinical workload and scheduling procedures. Institutional and cultural diversity among health care providers and volunteers fosters the mobilisation of knowledge resources, synergistic collaboration, and tailored care standards that align with both provider and patient expectations. By integrating these diverse, distributed networks, a synergistic effect is achieved, combining effective learning mechanisms with intellectual capital.Our study provides insights into the structure, implementation strategies, dissemination methodologies, and initial results of THU's operation. These findings may inform future emergency telemedicine responses in humanitarian scenarios, thereby reinforcing the practical implementation of health as a human right.

  View details for DOI 10.7189/jogh.14.04158

  View details for PubMedID 39451063

• India's evolving digital health strategy. NPJ digital medicine Narayan, A., Bhushan, I., Schulman, K. 2024; 7 (1): 284

  View details for DOI 10.1038/s41746-024-01279-2

  View details for PubMedID 39414924

  View details for PubMedCentralID 3093249

• To Err Is Human: A Quarter Century of Progress. Journal of general internal medicine Narayan, A., Kaplan, R. M., Adashi, E. Y. 2024

  View details for DOI 10.1007/s11606-024-09087-w

  View details for PubMedID 39375317

  View details for PubMedCentralID 7979747

• Cervical cancer disparities in stage at presentation for disaggregated Asian Americans, Native Hawaiians, and Pacific Islanders. American journal of obstetrics and gynecology Ho, F. D., Thaploo, A., Wang, K., Narayan, A., Alberto, I. R., Ong, E. P., Kohli, K., Kohli, M., Jain, B., Dee, E. C., Gomez, S. L., Janopaul-Naylor, J., Chino, F. 2024

  Abstract

  Over 20 million people in the United States identified as Asian American, Native Hawaiian, or Pacific Islander (AANHPI) in 2022. Despite the diversity of immigration histories, lived experiences, and health needs within the AANHPI community, prior studies in cervical cancer have considered this group in aggregate.We sought to analyze disparities in cervical cancer stage at presentation in the United States, focusing on disaggregated AANHPI groups.Data from the United States National Cancer Database from 2004 to 2020 of 122,926 patients newly diagnosed with cervical cancer was retrospectively analyzed. AANHPI patients were disaggregated by country of origin. Logistic regression, adjusted for clinical and sociodemographic factors, was used to calculate adjusted odds ratios. Higher adjusted odds ratios indicate an increased likelihood of metastatic versus non-metastatic disease at diagnosis.Out of 122,926 patients with cervical cancer, 5,142 (4.2%) identified as AANHPI. Compared to non-Hispanic White (NHW) patients, pooled AANHPI patients presented at lower stages of cancer (NHW: 58.7% diagnosed local/regional, AANHPI: 85.6% at local/regional, χ2 P<0.001). The largest AANHPI subgroups included Filipino Americans (n=1051, 20.4% of AANHPI), Chinese Americans (n=995, 19.4%), Asian Indian/Pakistani Americans (n=711, 13.8%), Vietnamese Americans (n=627, 12.2%), and Korean Americans (n=550, 10.7%) respectively. AANHPI disaggregation revealed that Pacific Islander American patients had higher odds of presenting with metastatic disease (aOR 1.58, 95% CI 1.21-2.06, p = 0.001) relative to non-Hispanic White patients. Conversely, Chinese American (aOR 0.47, 95% CI 0.37-0.59, p < 0.001), Vietnamese American (aOR 0.54, 95% CI 0.41-0.70, p < 0.001), Hmong American (aOR 0.46, 95% CI 0.22-0.97, p = 0.040), and Indian/Pakistani American (aOR 0.76, 95% CI 0.61-0.94, p = 0.013) patients were less likely to present with metastatic disease. Compared to the largest AANHPI group (Chinese American), nine other subgroups were more likely to present with metastatic disease. The largest differences were observed in Pacific Islander American (aOR 3.44, 95% CI 2.41-4.91, p < 0.001), Thai American (aOR 2.79, 95% CI 1.41-5.53, p = 0.003), Kampuchean American (aOR 2.39, 95% CI 1.29-4.42, p = 0.006), Native Hawaiian American (aOR 2.23, 95% CI 1.37-3.63, p = 0.001), and Laotian American (aOR 2.02, 95% CI 1.13-3.61, p = 0.017). In contrast, Vietnamese American (aOR 1.20, 95% CI 0.85-1.71, p = 0.303) and Hmong American (aOR 1.09, 95% CI 0.50-2.37, p = 0.828) patients did not show a statistically significant difference in presenting with metastatic disease compared to Chinese American patients.Aggregated evaluation of the Asian American, Native Hawaiian, or Pacific Islander monolith masks disparities in outcomes for distinct populations at risk for equity gaps. This disaggregation study shows that marginalized groups within the larger AANHPI population - including Pacific Islander American and Thai American patients - may face different exposures and larger structural barriers to cancer screening and early-stage diagnosis. A future focus on community based disaggregated research and tailored interventions is necessary to close these gaps.

  View details for DOI 10.1016/j.ajog.2024.08.027

  View details for PubMedID 39179090

• Dying with dignity: how can we deliver values-concordant end-of-life care for immigrant patients in the United States? Lancet regional health. Americas Kohli, K., Feliciano, E. J., Swami, N., Narayan, A., Patel, T. A., Jain, B., Iyengar, P., Kanevsky, J., Nguyen, P. L., Dee, E. C. 2024; 35: 100776

  View details for DOI 10.1016/j.lana.2024.100776

  View details for PubMedID 38803546

  View details for PubMedCentralID PMC11128497

• Beyond Brick and Mortar: The Rise of Street Medicine. Journal of general internal medicine Narayan, A., Shah, N., Hochman, M. 2024

  Abstract

  In 2023, approximately 650,000 people experienced homelessness (PEH) nightly in the United States, the highest number recorded in the country's history. This alarming statistic has made homelessness a key issue in the 2024 elections, especially with the White House's goal to reduce homelessness by 25% by 2025. Despite efforts and investments, homelessness remains a persistent public health challenge. The recent inclusion of street medicine services in Center for Medicare and Medicaid Services (CMS) billing codes represents a significant step forward. Street medicine, defined by CMS as healthcare provided in non-permanent locations to unsheltered individuals, now qualifies for Medicare reimbursement. This policy change, alongside state-level initiatives, aims to improve healthcare access for the unhoused, particularly older adults. However, challenges remain in establishing adequate fee schedules and integrating care management. Despite these obstacles, the integration of healthcare and housing services is crucial for addressing homelessness effectively, promoting stability, and improving health outcomes for PEH. This manuscript explores the history, practical guidance, and potential impacts of these developments on homelessness and public health.

  View details for DOI 10.1007/s11606-024-08880-x

  View details for PubMedID 38937362

  View details for PubMedCentralID 4520328

• Challenges With Relying on Body Fat and Weight Values for Obesity-Reply. JAMA internal medicine Narayan, A., Agarwal, A. A., Stanford, F. C. 2024

  View details for DOI 10.1001/jamainternmed.2024.2376

  View details for PubMedID 38884971

• Cervical cancer disparities in stage at presentation for disaggregated Asian Americans, Native Hawaiians, and Pacific Islanders Thaploo, A., Ho, F., Wang, K., Narayan, A., Alberto, I., Ong, E., Kohli, K., Kohli, M., Jain, B., Dee, E., Gomez, S. L., Janopaul-Naylor, J., Chino, F. LIPPINCOTT WILLIAMS & WILKINS. 2024

  View details for Web of Science ID 001275557401381

• Food and Drug Omnibus Reform Act: A Critical Course Correction. Mayo Clinic proceedings Narayan, A., Cohen, I. G., Adashi, E. Y. 2024

  View details for DOI 10.1016/j.mayocp.2024.01.016

  View details for PubMedID 38661597

• An Over-the-Counter Contraceptive Is Approved: The Reproductive Autonomy Imperative. Journal of general internal medicine Narayan, A., Adashi, E. Y. 2024

  View details for DOI 10.1007/s11606-024-08749-z

  View details for PubMedID 38587727

• Decentralizing Health Care: History and Opportunities of Web3. JMIR formative research Narayan, A., Weng, K., Shah, N. 2024; 8: e52740

  Abstract

  This paper explores the relationship between the development of the internet and health care, highlighting their parallel growth and mutual influence. It delves into the transition from the early, static days of Web 1.0, akin to siloed physician expertise in health care, to the more interactive and patient-centric era of Web 2.0, which was accompanied by advancements in medical technologies and patient engagement. This paper then focuses on the emerging era of Web3-the decentralized web-which promises a transformative shift in health care, particularly in how patient data are managed, accessed, and used. This shift toward Web3 involves using blockchain technology for decentralized data storage to enhance patient data access, control, privacy, and value. This paper also examines current applications and pilot projects demonstrating Web3's practical use in health care and discusses key questions and considerations for its successful implementation.

  View details for DOI 10.2196/52740

  View details for PubMedID 38536235

• Body Composition in Anti-Obesity Medication Trials-Beyond Scales. JAMA internal medicine Agarwal, A. A., Narayan, A., Stanford, F. C. 2024

  View details for DOI 10.1001/jamainternmed.2023.7733

  View details for PubMedID 38372971

• A Person-Centered Approach to Kidney Care NEJM CATALYST INNOVATIONS IN CARE DELIVERY Liou-Johnson, V., Narayan, A., Odama, U., Weber, K., Shah, N. R. 2024; 5 (2)

  View details for DOI 10.1056/CAT.23.0376

  View details for Web of Science ID 001354392800003

• Place of Death Before and During the COVID-19 Pandemic. JAMA network open Teasdale, B., Narayan, A., Harman, S., Schulman, K. A. 2024; 7 (1): e2350821

  View details for DOI 10.1001/jamanetworkopen.2023.50821

  View details for PubMedID 38190187

• Structural Sequelae of the COVID Pandemic: The Youth Mental Health Crisis. Pediatrics Narayan, A., Chao, S. D. 2023

  Abstract

  A year ago, 17-year-old "Alex" was brought into the emergency department after a self-inflicted gunshot wound. Neither his primary care doctor nor his psychologist were aware of his first attempt 6 months previously. Unfortunately, this attempt was successful. It occurred in front of his home, and in front of his mother who was just seconds too late to stop him. In the aftermath, we wondered why the medical system that he had access to could not intervene in time.

  View details for DOI 10.1542/peds.2023-062963

  View details for PubMedID 38050425

• Building Bridges With School Boards-An Understudied Seat of Health Equity. JAMA pediatrics Narayan, A., DeLine-Caballero, S. S., Prober, C. G. 2023

  View details for DOI 10.1001/jamapediatrics.2023.4226

  View details for PubMedID 37870854

• Prioritizing persons deprived of liberty in global guidelines for tuberculosis preventive treatment. PLoS medicine Narayan, A., Salindri, A. D., Keshavjee, S., Muyoyeta, M., Velen, K., Rueda, Z. V., Croda, J., Charalambous, S., García-Basteiro, A. L., Shenoi, S. V., Gonçalves, C. C., Ferreira da Silva, L., Possuelo, L. G., Aguirre, S., Estigarribia, G., Sequera, G., Grandjean, L., Telisinghe, L., Herce, M. E., Dockhorn, F., Altice, F. L., Andrews, J. R. 2023; 20 (10): e1004288

  Abstract

  In this Policy Forum piece, Aditya Narayan and colleagues discuss the challenges and opportunities for tuberculosis preventive treatment in carceral settings.

  View details for DOI 10.1371/journal.pmed.1004288

  View details for PubMedID 37788448

  View details for PubMedCentralID PMC10547494

• Employer-Based Health Insurance and Employee Compensation. JAMA health forum Schulman, K., Narayan, A. 2023; 4 (3): e225486

  Abstract

  This Viewpoint expounds on how the cost of health insurance is consuming an ever-greater share of total compensation for employers and employees, stagnating real incomes and calling into question its real value.

  View details for DOI 10.1001/jamahealthforum.2022.5486

  View details for PubMedID 36897580

• Continuous monitoring of eating and sleeping behaviors in the home environments of older adults: a case study demonstration. Frontiers in public health Narayan, A., Goncharova, M., Goncharov, M., Gostine, A., Shah, N. R., Kaplan, R. M. 2023; 11: 1277714

  Abstract

  Accurate observation of patient functioning is necessary for rigorous clinical research and for improving the quality of patient care. However, clinic or laboratory environments systematically differ from the contexts of everyday life. Further, assessments that are completed in a single institutional session may not be generalizable. Here, we describe a computer vision methodology that measures human functioning continuously in the environments where patients live, sleep, and eat.

  View details for DOI 10.3389/fpubh.2023.1277714

  View details for PubMedID 38283288

  View details for PubMedCentralID PMC10811267

• Retinoblastoma Detection via Image Processing and Interpretable Artificial Intelligence Techniques Duraivenkatesh, S., Narayan, A., Srikanth, V., Made, A., IEEE IEEE COMPUTER SOC. 2023: 166-167

  View details for DOI 10.1109/CAI54212.2023.00079

  View details for Web of Science ID 001046447800069